Page 59 - Multidisipliner Covid 19
P. 59

SARS-CoV-2 Özellikleri ve Laboratuvar Tan›s›


                      2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):
                      497_506. doi:10.1016/S0140-6736(20)30183-5
                   19. Xiong C, Jiang L, Chen Y, Jiang Q. Evolution and variation of 2019-
                      novel coronavirus. bioRxiv January 30, 2020 doi:10.1101/2020.01.30.
                      926477
                   20. Yu W, Tang G, Zhang L, Corlett RT. Decoding evolution and transmis-
                      sions of novel pneumonia coronavirus using the whole genomic data.
                      ChinaXiv. 2020. doi:10.12074/202002.00033
                   21. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. Theprox-
                      imal origin of SARS-CoV-2. Nature Medicine 2020;26:450-452.
                   22. The biggest mystery: what it will take to trace the coronavirus source.
                      Nature, article.https://www.nature.com/articles/d41586-020-01541-
                      z. (erişim: 05. Haziran2020)
                   23. Genomic epidemiology of hCoV-19.https://www.gisaid.org/epiflu-
                      applications/next-hcov-19-app/. GISAID (erişim: 15. Haziran2020)
                   24. Park WB, Kwon NJ, Choi SJ, et al.   Virus Isolation from the First Pa-
                      tient with SARS-CoV-2 in Korea. J Korean Med Sci. Feb 2020;35(7):84.
                      https://doi.org/10.3346/jkms.2020.35.e84
                   25. Wu A, Peng Y, Huang B, et al. Genome Composition and Divergence
                      of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host
                      Microbe. 2020;27(3):325-328. doi:10.1016/j.chom.2020.02.001
                   26. Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019
                      novel human-pathogenic coronavirus isolated from a patient with
                      atypical pneumonia after visiting Wuhan. Emerging Microbes & Infec-
                      tions.2020;9(1):,221-236,doi: 10.1080/22221751.2020.1719902
                   27. Chu H, Chan JFW, Wang Y, et al. Comparative replication and immune
                      activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an
                      ex vivo study with implications for the pathogenesis of COVID-19,
                      Clinical Infectious Diseases. 09 April 2020 https://doi.org/10.1093/
                      cid/ciaa410.
                   28. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell
                      Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically
                      Proven Protease Inhibitor. Cell Press. April 16, 2020; 181: 271–280.
                       https://doi.org/10.1016/j.cell.2020.02.052.
                   29. Ge XY, Li JL, Yang XL, et al. Isolation and characterization of a bat
                      SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503
                      (7477):535-538. doi:10.1038/nature12711




                        58
   54   55   56   57   58   59   60   61   62   63   64